<DOC>
	<DOC>NCT01419717</DOC>
	<brief_summary>This trial will facilitate access of denosumab for subjects with advanced cancer who have participated in a denosumab phase 3 study until denosumab is approved and available for sale, or until another mechanism is identified to provide denosumab to ongoing subjects.</brief_summary>
	<brief_title>Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>Subject was previously enrolled in a denosumab phase 3 study and participated in the Openlabel Extension portion of that study. Subject or subject's legally acceptable representative has provided informed consent. Subject is of child bearing potential and planning to become pregnant within 7 months after the end of treatment. Subject is of child bearing potential and is not willing to use, in combination with her partner, two highly effective methods of contraception during treatment and for 7 months after the end of treatment. Subject has known sensitivity to any of the products to be administered during dosing. Subject will not be available for protocol required study visits or procedures, to the best of the subject and investigator's knowledge. Subject has any kind of disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent and/or to comply with all required study procedures.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>cancer</keyword>
	<keyword>bone metastases</keyword>
	<keyword>breast cancer</keyword>
	<keyword>prostate cancer</keyword>
</DOC>